BioCentury | Feb 7, 2011
Strategy

Networked in China

Recent China-focused deals by Ligand Pharmaceuticals Inc. and Harbor BioSciences Inc. provide a roadmap for small biotechs looking to execute a China strategy. The key is personal networking. In January, Ligand granted Chiva Pharmaceuticals Inc....
BC Week In Review | Jan 10, 2011
Company News

Ligand, Hainan Kaihua deal

Ligand granted Hainan Kaihua's Chiva Pharmaceuticals Inc. affiliate rights in China to develop and commercialize HBV candidate Pradefovir and liver cancer candidate MB01733. Both compounds use Ligand's HepDirect liver targeting technology. Pradefovir is a prodrug...
BioCentury | Jan 10, 2011
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biotie Therapies Corp. (HSE:BTH1V) gained €0.18 (36%) to €0.68 on Monday after partner H. Lundbeck A/S (CSE:LUN) said it plans to submit an MAA next half for nalmefene to treat alcohol addiction. Biotie...
BC Extra | Jan 7, 2011
Company News

Ligand, Chiva in HepDirect deal

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted Chiva Pharmaceuticals Inc. rights in China to develop and commercialize HBV candidate Pradefovir and liver cancer candidate MB01733. Both compounds use Ligand's HepDirect liver targeting technology. Pradefovir is a prodrug...
Items per page:
1 - 4 of 4
BioCentury | Feb 7, 2011
Strategy

Networked in China

Recent China-focused deals by Ligand Pharmaceuticals Inc. and Harbor BioSciences Inc. provide a roadmap for small biotechs looking to execute a China strategy. The key is personal networking. In January, Ligand granted Chiva Pharmaceuticals Inc....
BC Week In Review | Jan 10, 2011
Company News

Ligand, Hainan Kaihua deal

Ligand granted Hainan Kaihua's Chiva Pharmaceuticals Inc. affiliate rights in China to develop and commercialize HBV candidate Pradefovir and liver cancer candidate MB01733. Both compounds use Ligand's HepDirect liver targeting technology. Pradefovir is a prodrug...
BioCentury | Jan 10, 2011
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biotie Therapies Corp. (HSE:BTH1V) gained €0.18 (36%) to €0.68 on Monday after partner H. Lundbeck A/S (CSE:LUN) said it plans to submit an MAA next half for nalmefene to treat alcohol addiction. Biotie...
BC Extra | Jan 7, 2011
Company News

Ligand, Chiva in HepDirect deal

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted Chiva Pharmaceuticals Inc. rights in China to develop and commercialize HBV candidate Pradefovir and liver cancer candidate MB01733. Both compounds use Ligand's HepDirect liver targeting technology. Pradefovir is a prodrug...
Items per page:
1 - 4 of 4